ONC

#400
BeOne Medicines Ltd. American Depositary Shares
311.6100 USD
+1.95%
Сектор:
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
305.8800
313.3500
Годовой диапазон
271.4701
385.2200
Дневное изменение
+1.95%
Месячное изменение
+8.91%
6-месячное изменение
-1.30%
Годовое изменение
-1.30%
Предыдущее закрытие
305.6400
Открыть
305.8800
Bid
Ask
Минимум
305.8800
High
313.3500
Объем
141
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 34.571 B
  • Employee 12 K
  • Founded 2010
  • CEO John Vincent OylerJohn Vincent Oyler
  • Website www.beonemedicines.com
  • Headquarter N/A
  • FIGI BBG00B6WF7T5
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
1 599
Коэффициент цена/денежный поток
83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.